In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.
Patients 18-years and older with and without heart failure (across all left ventricular ejection fraction) and cardiomyopathies including amyloidosis will be enrolled in this single center, longitudinal observational Registry. Baseline and one-year follow up blood samples including DNA as well as clinical characteristics, events leading up to heart failure diagnosis, etiology of heart failure, the presence and duration of other medical problems, laboratory, echocardiographic data and images, and therapy information will be obtained. Clinical outcomes of interest include major adverse cardiovascular events (a combination of all-cause death and heart failure hospitalizations), individual endpoints of all-cause death, cardiovascular death, all-cause hospitalization, cardiovascular hospitalization, heart failure hospitalization, right-sided heart failure, and kidney injury. Results from the Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) trial will comprehensively examine longitudinal clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand pathophysiology of heart failure and phenotypes in heart failure with an ultimate goal of improving precision medicine in heart failure.
Study Type
OBSERVATIONAL
Enrollment
3,000
Massachusetts General Hospital
Boston, Massachusetts, United States
RECRUITINGMajor adverse cardiovascular events (MACE)
MACE as defined by a combined end point of all-cause mortality and HF hospitalizations.
Time frame: Time from sample collection until the date of documented event up to 60 months after the study closure.
Time to event: all-cause mortality
Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events.
Time frame: Time from sample collection until the date of documented event up to 60 months after the study closure.
Time to event: cardiovascular mortality
Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events.
Time frame: Time from sample collection until the date of documented event up to 60 months after the study closure.
Time to event: all-cause hospitalization
Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events.
Time frame: Time from sample collection until the date of documented event up to 60 months after the study closure.
Time to event: cardiovascular hospitalization
Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events.
Time frame: Time from sample collection until the date of documented event up to 60 months after the study closure.
Time to event: HF hospitalization
Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events.
Time frame: Time from sample collection until the date of documented event up to 60 months after the study closure.
Time to event: Right-sided HF
Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events.
Time frame: Time from sample collection until the date of documented event up to 60 months after the study closure.
Time to event: acute kidney injury
Medical records and phone follow-up with patients and/or their physicians will allow the investigators to ascertain vital status and any significant clinical events.
Time frame: Time from sample collection until the date of documented event up to 60 months after the study closure.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.